Pharma channel feed

As­traZeneca chair­man re­peats their po­si­tion on in­vest­ing in UK dur­ing Brex­it talks, trig­ger­ing fresh fears

7 years ago

Sanofi Gen­zyme has its ex­pan­sive sights set on a new tech cam­pus in Cam­bridge — re­port

7 years ago

SQZ play: Roche dou­bles down on a $1.37B-plus deal for a new ap­proach to im­muno-on­col­o­gy out of Bob Langer's lab

7 years ago

Ex­perts of­fer a sol­id en­dorse­ment for Acel­Rx pain med, spurring a big ral­ly for their stock

7 years ago

FDA sets record for num­ber of gener­ic drug ap­provals again

7 years ago

Ab­b­Vie staves off an­oth­er US Hu­mi­ra knock­off to 2023 as Eu­ro­pean launch looms

7 years ago

Hit by FDA red flags, cit­ed for mis­lead­ing in­vestors and bat­tered by a thumbs-down from ex­perts, it’s been one ter­ri­ble week for Treve­na

7 years ago

Acel­Rx ral­ly quick­ly fiz­zles af­ter FDA of­fers a guard­ed warn­ing about its lat­est pain drug pitch

7 years ago

Trump signs bills to elim­i­nate phar­ma­cy ‘gag’ claus­es

7 years ago

Te­va-part­nered Cell­tri­on biosim­i­lar scores FDA ad­comm rec­om­men­da­tion for a sec­ond shot at shak­ing up Roche's Rit­ux­an fran­chise

7 years ago

Bris­tol-My­ers em­braces a pos­si­ble check­point col­lab­o­ra­tor, snag­ging a batch of stock and lin­ing up a po­ten­tial deal

7 years ago

CRISPR Ther­a­peu­tics, Ver­tex set for first sick­le cell dis­ease tri­al af­ter FDA lifts clin­i­cal hold — just don't look for any ex­pla­na­tion

7 years ago

Roche puts down $75M to sign on as new part­ner for Ion­is' dry AMD drug, fol­low­ing Hunt­ing­ton's deal

7 years ago

Drop in clin­i­cal tri­al num­bers un­der­scores drug­mak­er­s' fears over Brex­it that trace back over a year

7 years ago
R&D

No­var­tis builds its case for a new sick­le cell drug, eye­ing a de­layed FDA fil­ing in ‘19

7 years ago
R&D

Treve­na crushed as an­a­lysts count red flags in FDA’s re­view of its new pain med

7 years ago

Re­or­ga­ni­za­tion of OND to sup­port new drug re­view mod­ern­iza­tion, Wood­cock says

7 years ago

No­var­tis bets PRV on its next big mul­ti­ple scle­ro­sis drug — eyes US, EU ap­provals in '19

7 years ago

Io­n­is and Akcea get their shot at com­pet­ing with Al­ny­lam for a rare dis­ease group — but it’s not ex­pect­ed to be pret­ty

7 years ago

With its rep on the line, Cel­gene's new­ly-filed safe­ty study spurs fresh wor­ries over fate of ozan­i­mod

7 years ago

Ex­pand­ing on their in­fec­tious dis­ease deal, Sanofi turns to Evotec for its drug dis­cov­ery ex­per­tise

7 years ago

All revved up and ready to roll, Roche is hand­ed the keys to a multi­bil­lion-dol­lar he­mo­phil­ia mar­ket

7 years ago

J&J hands Ar­row­head a plum $3.7B deal for hep B-plus 3 — cor­ralling a pos­si­ble game-chang­ing RNAi drug

7 years ago

BIO warns mem­bers: No more rau­cous af­ter-hours events — and start putting women in se­nior posts, now

7 years ago
First page Previous page 289290291292293294295 Next page Last page
A service from the Financial Times